- Home
- PAVM vs VRAX Comparison
PAVM vs VRAX Comparison
Compare PAVM & VRAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PAVM | VRAX |
|---|---|---|
| Founded | 2014 | 2013 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.5M | 2.9M |
| IPO Year | 2016 | 2022 |
Fundamental Metrics
Financial Performance| Metric | PAVM | VRAX |
|---|---|---|
| Price | $7.38 | $0.41 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 1 |
| Target Price | ★ $510.00 | $3.00 |
| AVG Volume (30 Days) | 22.1K | ★ 570.8K |
| Earning Date | 11-13-2025 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $29,000.00 | $2,986.00 |
| Revenue This Year | N/A | $217,274.83 |
| Revenue Next Year | $450.56 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $6.00 | $0.31 |
| 52 Week High | $26.85 | $3.20 |
Technical Indicators
Market Signals| Indicator | PAVM | VRAX |
|---|---|---|
| Relative Strength Index (RSI) | 92.92 | 49.47 |
| Support Level | $0.21 | $0.33 |
| Resistance Level | $9.26 | $0.44 |
| Average True Range (ATR) | 0.44 | 0.04 |
| MACD | 0.85 | 0.01 |
| Stochastic Oscillator | 78.72 | 50.33 |
Price Performance
Historical ComparisonAbout PAVM PAVmed Inc.
PAVmed Inc is a multi-product, commercial-stage medical technology company organized to advance a broad pipeline of medical technologies from concept to commercialization. The company operates in a single segment as a medical technology company, with the following lines of business: Diagnostics, Medical Devices, and Digital Health. Its products are EsoGuard, esocheck, and the Veris Cancer Care Platform.
About VRAX Virax Biolabs Group Limited
Virax Biolabs Group Ltd is a biotechnology company focused on the prevention, detection, diagnosis and risk management of viral diseases that also engages in distribution of diagnostics test kits of various viral threats. It is developing a proprietary T-Cell Test technology with the intention of providing an immunology profiling platform that assesses each individual's immune risk profile against world-wide viral threats. T-Cell testing is particularly effective in the diagnosis and therapeutics of COVID-19 as well as other threats including Hepatitis B, Malaria, Herpes (HSV-1) and Human Papillomavirus (HPV).